{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NDA018827
(1984)
Source URL:
First approved in 1984
Source:
NDA018827
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 332
(2003)
Source URL:
First approved in 1984
Source:
NDA018917
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2010)
Source URL:
First approved in 1983
Source:
NDA018723
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 1983
Source:
NDA019555
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333
(2010)
Source URL:
First approved in 1983
Source:
NDA019555
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT04026438: Phase 4 Interventional Completed Complication, Postoperative
(2019)
Source URL:
First approved in 1983
Source:
NADA125961
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NDA018642
(1983)
Source URL:
First approved in 1983
Source:
NDA018642
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA218194
(1982)
Source URL:
First approved in 1982
Source:
ANDA218194
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NDA018613
(1982)
Source URL:
First approved in 1982
Source:
NDA018613
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M005
(2021)
Source URL:
First approved in 1981
Source:
ANDA086414
Source URL:
Class:
MIXTURE